Market ExpansionLiquidia has signed contracts with the three major commercial payers, which is expected to expand its investor audience.
Prescription GrowthThe launch of Yutrepia continues to accelerate, with more than 2,000 unique prescriptions and 1,500 patient starts to date.
Yutrepia Commercial SuccessThe early profitability of Yutrepia has shifted Liquidia's story from a binary launch to a profit-driven one, attracting a more diverse shareholder base.